Parkinson Disease Pharmacotherapy
On this page
Direct answer
Levodopa, always co-prescribed with carbidopa, remains the most effective symptomatic drug for Parkinson disease — the standard start is one 100/25 mg tablet three times daily, titrated to response, with at least 70-100 mg of daily carbidopa needed to quiet peripheral dopa-decarboxylase and the nausea it causes. Its long-term problems are pharmacodynamic, not mysterious: after about five years, roughly half of patients develop wearing-off and dyskinesia, which is why younger patients sometimes open with dopamine agonists (pramipexole, ropinirole) — trading earlier levodopa complications for impulse-control disorders, somnolence and hallucinations. Around the core sit the adjuncts: amantadine (the one drug that mutes levodopa dyskinesia), rasagiline and entacapone stretching each levodopa dose, and apomorphine as a rescue injection. Two contraindication rules close the prescribing circle: metoclopramide and haloperidol are forbidden in parkinsonism, and psychosis is managed with quetiapine or clozapine, never the typical antipsychotics.
What you must remember
- Levodopa-carbidopa mechanics: absorbed by neutral amino acid transport — separate from protein-heavy meals; carbidopa keeps peripheral conversion (and nausea) down; 100/25 three times daily is the classic start.
- Motor complications timeline: wearing-off, on-off fluctuation and dyskinesia in about half of patients by five years — the reason for dose-sparing strategies, not for withholding levodopa when function demands it.
- Dopamine agonists: pramipexole and ropinirole — impulse-control disorders (pathological gambling, hypersexuality, compulsive shopping) mandate explicit counselling; sudden sleep attacks and hallucinations limit use in the elderly; ergot agonists are gone (valvulopathy).
- Amantadine: the established antidyskinesia agent (N-methyl-D-aspartate antagonism) — also mildly effective early; confusion and livedo reticularis at higher doses.
- MAO-B inhibitors: rasagiline for early mild disease and as adjunct; avoid with pethidine and dextromethorphan (serotonin syndrome) — selegiline's amphetamine metabolite disturbs sleep.
- COMT inhibitor: entacapone 200 mg with each levodopa dose extends each dose's action — the standard move for wearing-off.
- Apomorphine: subcutaneous rescue for off episodes — profound nausea needs domperidone cover; the antiemetic question in disguise.
- Forbidden and preferred: metoclopramide, haloperidol and other D2 blockers worsen parkinsonism; quetiapine (or clozapine with blood monitoring) for psychosis; domperidone (outside cardiac cautions) is the antiemetic that spares the brain.
A worked clinic decade
A 58-year-old truck driver presents with right-hand tremor, stiffness and micrographia. Opening strategy: because he drives for a living and his symptoms impair work, levodopa-carbidopa 100/25 three times daily is chosen over an agonist — somnolence and sudden-onset sleep disqualify pramipexole for a professional driver, an applied detail worth marking. Response is excellent for four years. Then the doses begin expiring before the next is due — wearing-off. First move: fractionate levodopa into smaller, more frequent doses and separate it from his protein-heavy lunches. Next: add entacapone 200 mg with each dose. When dystonic choreiform movements appear at peak dose, amantadine enters and the dyskinesia softens.
By year twelve, visual hallucinations of people in the house begin. The reflex of haloperidol would be catastrophic; quetiapine at night is titrated with the family warned about sedation, and clozapine remains in reserve with its mandatory blood-count programme. The decade illustrates the whole topic: one effective drug, managed against its own complications.
How the exam frames it
The recurring marks are pairings: dopamine agonists with impulse-control disorders; amantadine with dyskinesia suppression; apomorphine with domperidone cover; rasagiline with the pethidine-dextromethorphan interaction. The contraindication question is near-annual: "which antiemetic is safe in Parkinson disease?" — domperidone (peripheral D2 antagonism, minimal brain entry), while metoclopramide and haloperidol are the traps. A second layer tests concepts over lists: why fractionate levodopa (short half-life and transport competition with dietary protein), and why younger patients might start with agonists (delaying levodopa complications at the price of neuropsychiatric ones) — questions asking for the trade-off, not the drug name. The Indian-context thread is availability and cost: levodopa-carbidopa, pramipexole and trihexyphenidyl are the affordable backbone of Indian prescriptions, while apomorphine, duodenal levodopa infusion and deep-brain stimulation cluster in a handful of centres — a candidate who pairs the ideal algorithm with the Indian reality of what patients can fill monthly writes the answer examiners remember.
Frequently asked questions
What is the most effective drug for Parkinson disease?
Levodopa with carbidopa — no agent surpasses it for bradykinesia and rigidity; everything else is adjunct or alternative.
Which drug reduces levodopa-induced dyskinesia?
Amantadine — the established antidyskinesia agent through NMDA-receptor antagonism.
What psychiatric adverse effect demands counselling before pramipexole?
Impulse-control disorders — pathological gambling, hypersexuality, compulsive spending — plus sudden sleep attacks.
Why is metoclopramide contraindicated in parkinsonism?
Its central D2 blockade worsens parkinsonian symptoms; domperidone, which barely crosses the blood-brain barrier, is the safer antiemetic.
How should levodopa be timed relative to meals?
Separated from high-protein meals, because dietary amino acids compete for its intestinal transport and blunt absorption.